<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title>Arthritis Research &#x00026; Therapy</journal-title><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ar2136</article-id><article-id pub-id-type="pmid">17341301</article-id><article-id pub-id-type="doi">10.1186/ar2136</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>CTLA-4 </italic>+49A/G and CT60 gene polymorphisms in primary Sj&#x000f6;gren syndrome</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Gottenberg</surname><given-names>Jacques-Eric</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jegotten@club-internet.fr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Loiseau</surname><given-names>Pascale</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>pascale.loiseau@paris7.jussieu.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Azarian</surname><given-names>Mariam</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mariam.azarian@paris7.jussieu.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Chen</surname><given-names>Chun</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>chun.chen@paris7.jussieu.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Cagnard</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>nicolas.cagnard@wanadoo.fr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Hachulla</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>ehachulla@chru-lille.fr</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Puechal</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>xpuechal@ch-lemans.fr</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Sibilia</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>jean.sibilia@wanadoo.fr</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Charron</surname><given-names>Dominique</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>charron@histo.chu-stlouis.fr</email></contrib><contrib id="A10" corresp="yes" contrib-type="author"><name><surname>Mariette</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>xavier.mariette@bct.aphp.fr</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Miceli-Richard</surname><given-names>Corinne</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>corinne.miceli@bct.aphp.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>Rhumatologie, Institut Pour la Sant&#x000e9; et la Recherche M&#x000e9;dicale (INSERM) U802, Universit&#x000e9; Paris-Sud 11, H&#x000f4;pital Bic&#x000ea;tre, 78 rue du G&#x000e9;n&#x000e9;ral Leclerc, Assistance Publique-H&#x000f4;pitaux de Paris (AP-HP), 94275 Le Kremlin Bic&#x000ea;tre, France</aff><aff id="I2"><label>2</label>INSERM 396, Immunologie et Histocompatibilit&#x000e9;, H&#x000f4;pital Saint-Louis, 1 avenue Claude-Vellefaux, AP-HP, 75475 Paris cedex 10, France</aff><aff id="I3"><label>3</label>Institut Cochin, Unit&#x000e9; de biologie mol&#x000e9;culaire, H&#x000f4;pital Cochin, 27 rue du Faubourg Saint-Jacques, 75679 Paris cedex 14, France</aff><aff id="I4"><label>4</label>M&#x000e9;decine Interne, H&#x000f4;pital Claude Huriez, 2 avenue Oscar Lambret, 59000 Lille, France</aff><aff id="I5"><label>5</label>Rhumatologie, H&#x000f4;pital du Mans, 194 avenue Rubillard, 72037 Le Mans, France</aff><aff id="I6"><label>6</label>Rhumatologie, H&#x000f4;pital Hautepierre, 1 avenue Moli&#x000e8;re, 67098 Strasbourg, France</aff><pub-date pub-type="ppub"><year>2007</year></pub-date><pub-date pub-type="epub"><day>6</day><month>3</month><year>2007</year></pub-date><volume>9</volume><issue>2</issue><fpage>R24</fpage><lpage>R24</lpage><ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/9/2/R24"/><history><date date-type="received"><day>23</day><month>11</month><year>2006</year></date><date date-type="rev-request"><day>9</day><month>1</month><year>2007</year></date><date date-type="rev-recd"><day>5</day><month>2</month><year>2007</year></date><date date-type="accepted"><day>6</day><month>3</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Gottenberg et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Gottenberg et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Gottenberg Jacques-Eric jegotten@club-internet.fr </dc:author><dc:title> CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sj&#x000f6;gren syndrome </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>Arthritis Research &#x00026; Therapy 9(2): R24-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1478-6354(2007)9:2&#x0003c;R24&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1478-6354</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p><italic>CTLA-4 </italic>encodes cytotoxic T lymphocyte-associated antigen-4, a cell-surface molecule providing a negative signal for T-cell activation. <italic>CTLA-4 </italic>gene polymorphisms have been widely studied in connection with genetic susceptibility to various autoimmune diseases, but studies have led to contradictory results in different populations. This case-control study sought to investigate whether <italic>CTLA-4 </italic>CT60 and/or +49A/G polymorphisms were involved in the genetic predisposition to primary Sj&#x000f6;gren syndrome (pSS). We analysed <italic>CTLA-4 </italic>CT60 and +49A/G polymorphisms in a first cohort of 142 patients with pSS (cohort 1) and 241 controls, all of Caucasian origin. A replication study was performed on a second cohort of 139 patients with pSS (cohort 2). In cohort 1, the <italic>CTLA-4 </italic>+49A/G*A allele was found on 73% of chromosomes in patients with pSS, compared with 66% in controls (<italic>p </italic>= 0.036; odds ratio (OR) 1.41, 95% confidence interval (CI) 1.02 to 1.95). No difference in <italic>CTLA-4 </italic>CT60 allelic or genotypic distribution was observed between patients (<italic>n </italic>= 142) and controls (<italic>n </italic>= 241). In the replication cohort, the <italic>CTLA-4 </italic>+49A/G*A allele was found on 62% of chromosomes in patients with pSS, compared with 66% in controls (<italic>p </italic>= 0.30; OR 0.85, 95% CI 0.63 to 1.16). Thus, the <italic>CTLA-4 </italic>+49A/G*A allele excess among patients from cohort 1 was counterbalanced by its under-representation in cohort 2. When the results from the patients in both cohorts were pooled (<italic>n </italic>= 281), there was no difference in <italic>CTLA-4 </italic>+49A/G allelic or genotypic distribution in comparison with controls. Our results demonstrate a lack of association between <italic>CTLA-4 </italic>CT60 or +49A/G polymorphisms and pSS. Premature conclusions might have been made if a replication study had not been performed. These results illustrate the importance of case-control studies performed on a large number of patients. In fact, sampling bias may account for some contradictory results previously reported for <italic>CTLA-4 </italic>association studies in autoimmune diseases.</p></abstract></article-meta><notes><p>See related letter by Lester <italic>et al</italic>., <ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/9/3/401"/> and related letter by Miceli-Richard <italic>et al</italic>., <ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/9/3/402"/></p></notes></front><body><sec><title>Introduction</title><p>Polymorphisms in <italic>CTLA-4</italic>, the gene encoding cytotoxic T lymphocyte-associated antigen-4, have been widely studied in connection with genetic susceptibility to various autoimmune diseases [<xref ref-type="bibr" rid="B1">1</xref>], but studies have led to contradictory results in different populations.</p><p>Among <italic>CTLA-4 </italic>gene polymorphisms, a G to A transition at position 49 (+49A/G) of exon 1 leads to an alanine to threonine amino acid substitution at codon 17 in the leader peptide (A17T), and a C to T transition at position 60 (CT60) is located within the 3'-untranslated region [<xref ref-type="bibr" rid="B2">2</xref>]. The G allele of +49A/G has been associated with a predisposition to many autoimmune diseases (reviewed in [<xref ref-type="bibr" rid="B1">1</xref>]). Both polymorphisms are in linkage disequilibrium, which warrants haplotype analysis in studies of <italic>CTLA-4 </italic>polymorphisms. The CT60 G allele has been reported to increase susceptibility to several autoimmune diseases [<xref ref-type="bibr" rid="B2">2</xref>], and a functional approach provided evidence for lower mRNA levels associated with the CT60 G allele [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Downie-Doyle and colleagues have recently reported a significant association of the <italic>CTLA-4 </italic>+49A/G*A allele and of the <italic>CTLA-4 </italic>+49A/G*A allele carrier haplotypes with primary Sj&#x000f6;gren syndrome (pSS), especially in patients with anti-SSA or anti-SSB antibodies, in a study including 111 Australian patients with pSS and 156 controls [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>The aim of our study was to investigate in a large case-control study whether <italic>CTLA-4 </italic>CT60 and/or +49A/G SNPs were involved in genetic predisposition to pSS in French patients.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients</title><p>A first cohort of 142 unrelated patients with pSS diagnosed in accordance with the European American consensus group criteria [<xref ref-type="bibr" rid="B4">4</xref>] (37% without autoantibodies, 30% with anti-SSA antibodies only, and 33% with both anti-SSA and anti-SSB antibodies) and 241 healthy blood donors were genotyped for <italic>CTLA-4 </italic>CT60 and +49A/G polymorphisms. A second independent cohort of 139 patients with pSS was further genotyped for <italic>CTLA-4 </italic>+49A/G polymorphisms in a replication study. The geographical origin and the clinico-biological characteristics of the patients in this second cohort were the same as those in the first. In this second cohort, 27% of patients were anti-SSA and anti-SSB negative, 35% had anti-SSA only and 38% had both anti-SSA and anti-SSB. All patients and controls were Caucasians and provided informed consent.</p></sec><sec><title>Genotyping</title><p>After the isolation of genomic DNA from peripheral blood mononuclear cells, <italic>CTLA-4 </italic>CT60 and +49A/G polymorphisms were genotyped by restriction fragment length polymorphism with the use of <italic>Bbv</italic>I (+49A/G) and <italic>Nla</italic>III (CT60).</p></sec><sec><title>Statistical analysis</title><p>Allelic and genotypic frequencies of <italic>CTLA-4 </italic>CT60 and +49A/G polymorphisms were compared between patients and controls by using a two-sided &#x003c7;<sup>2 </sup>test. All genotyped SNPs were in Hardy&#x02013;Weinberg equilibrium. <italic>CTLA-4 </italic>(+49A/G or CT60) haplotypes, constructed with the PHASE program, were also examined for association with pSS. <italic>P </italic>&#x0003c; 0.05 was considered significant.</p></sec></sec><sec><title>Results</title><p>In the first cohort of patients with pSS, the A allele of the <italic>CTLA-4 </italic>+49A/G polymorphism was found on 73% of chromosomes in patients with pSS, in comparison with 66% in controls (<italic>p </italic>= 0.036, odds ratio (OR) 1.41, 95% confidence interval (CI) 1.02 to 1.95; Table <xref ref-type="table" rid="T1">1</xref>). No significant difference in <italic>CTLA-4 </italic>+49A/G*A allele frequencies was observed among subgroups of patients according to their anti-SSB and/or anti-SSA status (Table <xref ref-type="table" rid="T1">1</xref>). No difference in <italic>CTLA-4 </italic>CT60 allelic or genotypic distribution was observed between patients (<italic>n </italic>= 142) and controls (<italic>n </italic>= 241). <italic>CTLA-4 </italic>(+49A/G or CT60) haplotype distribution mirrored the <italic>CTLA-4 </italic>+49A/G*A allele excess among patients with pSS (A/A 48%, A/G 26%, G/G 26%, G/A 0.4%; in comparison with A/A 45%, A/G 21%, G/G 34% among controls), leading to an excess of +49A/G*A allele carrier haplotypes among patients (<italic>p </italic>= 0.03, OR 1.41, 95% CI 1.02 to 1.95).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Allellic frequencies of <italic>CTLA-4 </italic>49A/G polymorphism among patient controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><italic>CTLA-4</italic>+49A/G</td><td align="left" colspan="6">Allele frequencies</td><td align="left"><italic>p</italic></td><td align="left">Odds ratio (95% CI)</td></tr><tr><td></td><td colspan="6"><hr></hr></td><td></td><td></td></tr><tr><td></td><td align="left">pSS</td><td align="left">SSA+ and SSB+</td><td align="left">SSA+ only</td><td align="left">Ac+</td><td align="left">Ac0</td><td align="left">Controls (<italic>n </italic>= 241)</td><td></td><td></td></tr></thead><tbody><tr><td align="left">Cohort 1</td><td align="left"><italic>n </italic>= 142</td><td align="left"><italic>n </italic>= 47</td><td align="left"><italic>n </italic>= 43</td><td align="left"><italic>n </italic>= 90</td><td align="left"><italic>n </italic>= 52</td><td></td><td></td><td align="left">pSS vs controls</td></tr><tr><td align="left">&#x02003;A (Thr)</td><td align="left">208 (73)</td><td align="left">68 (72)</td><td align="left">61 (71)</td><td align="left">129 (72)</td><td align="left">79 (76)</td><td align="left">318 (66)</td><td align="left">0.036</td><td align="left">1.41 (1.02&#x02013;1.95)</td></tr><tr><td align="left">&#x02003;G (Ala)</td><td align="left">76 (27)</td><td align="left">26 (28)</td><td align="left">25 (29)</td><td align="left">51 (28)</td><td align="left">25 (24)</td><td align="left">164 (34)</td><td align="left">0.036</td><td align="left">0.70 (0.51&#x02013;0.98)</td></tr><tr><td align="left">Cohort 2</td><td align="left"><italic>n </italic>= 139</td><td align="left"><italic>n </italic>= 52</td><td align="left"><italic>n </italic>= 49</td><td align="left"><italic>n </italic>= 101</td><td align="left"><italic>n </italic>= 38</td><td align="left">Controls (<italic>n </italic>= 241)</td><td></td><td></td></tr><tr><td align="left">&#x02003;A (Thr)</td><td align="left">173 (62)</td><td align="left">59 (57)</td><td align="left">66 (67)</td><td align="left">125 (62)</td><td align="left">48 (63)</td><td align="left">318 (66)</td><td align="left">NS</td><td align="left">0.85 (0.62&#x02013;1.15)</td></tr><tr><td align="left">&#x02003;G (Ala)</td><td align="left">105 (38)</td><td align="left">45 (43)</td><td align="left">32 (33)</td><td align="left">77 (38)</td><td align="left">28 (37)</td><td align="left">164 (34)</td><td align="left">NS</td><td align="left">1.17 (0.86&#x02013;1.60)</td></tr><tr><td align="left">Total</td><td align="left"><italic>n </italic>= 281</td><td align="left"><italic>n </italic>= 99</td><td align="left"><italic>n </italic>= 92</td><td align="left"><italic>n </italic>= 191</td><td align="left"><italic>n </italic>= 90</td><td align="left">Controls (<italic>n </italic>= 241)</td><td></td><td></td></tr><tr><td align="left">&#x02003;A (Thr)</td><td align="left">381 (68)</td><td align="left">127 (64)</td><td align="left">127 (69)</td><td align="left">254 (66)</td><td align="left">127 (71)</td><td align="left">318 (66)</td><td align="left">NS</td><td align="left">1.08 (0.84&#x02013;1.40)</td></tr><tr><td align="left">&#x02003;G (Ala)</td><td align="left">181 (32)</td><td align="left">71 (36)</td><td align="left">57 (31)</td><td align="left">128 (34)</td><td align="left">53 (29)</td><td align="left">164 (34)</td><td align="left">NS</td><td align="left">0.92 (0.71&#x02013;1.19)</td></tr></tbody></table><table-wrap-foot><p>Numbers in parentheses are percentages. pSS, primary Sj&#x000f6;gren syndrome; Ac+, presence of anti SSB and/or anti-SSA; Ac0, absence of anti-SSA or anti-SSB antibody; CI, confidence interval; NS, not significant.</p></table-wrap-foot></table-wrap><p>To avoid the possibility of a false positive association of <italic>CTLA-4 </italic>+49A/G*A with pSS as a result of the somewhat small sample size of our first cohort, and because the <italic>CTLA-4 </italic>+49A/G*A allele has been only marginally associated with autoimmune diseases compared with the <italic>CTLA-4 </italic>+49A/G*G allele [<xref ref-type="bibr" rid="B1">1</xref>], we performed a replication study on a second independent cohort of 139 patients with pSS. In this second cohort, the <italic>CTLA-4 </italic>+49A/G*A allele was found on 62% of chromosomes in patients with pSS, compared with 66% in controls (<italic>p </italic>= 0.30; OR 0.85, 95% CI 0.63 to 1.16; Table <xref ref-type="table" rid="T1">1</xref>). Thus, the <italic>CTLA-4 </italic>+49A/G*A allele excess among patients with pSS from the first cohort was counterbalanced by its under-representation in the second cohort. When the results from the patients in both cohorts were pooled (<italic>n </italic>= 281), there was no difference in <italic>CTLA-4 </italic>+49A/G polymorphism allelic or genotypic distribution in comparison with controls (<italic>p </italic>= 0.53, OR 1.09, 95% CI 0.84 to 1.4; Table <xref ref-type="table" rid="T1">1</xref>). The sex ratios among patients (0.97) and controls (0.06) were different. We therefore investigated <italic>CTLA-4 </italic>+49A/G polymorphism genotypic distribution among males and females in the control group and found that it was not statistically different (<italic>p </italic>= 0.1), thus excluding any possible gender effect.</p><p>Our results therefore demonstrate a lack of association between <italic>CTLA-4 </italic>CT60 or +49A/G polymorphisms and pSS among Caucasians.</p></sec><sec><title>Discussion</title><p>The results from our first cohort were very close to those from the study of Downie-Doyle and colleagues [<xref ref-type="bibr" rid="B3">3</xref>], with a significant association of pSS with the +49A/G*A allele and with the +49A/G*A allele carriers haplotypes. The association observed in the first cohort, of two haplotypes bearing the same allele (<italic>CTLA-4 </italic>+49A/G*A), was actually more probably due to the statistical weight of the <italic>CTLA-4 </italic>+49A/G*A allele than to a true functional effect of two different haplotypes, bearing either <italic>CTLA-4 </italic>CT60*C or <italic>CTLA-4 </italic>CT60*T alleles, each having opposite functional effects on <italic>CTLA-4 </italic>mRNA expression [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>In fact, our results suggest a false positive association of <italic>CTLA-4 </italic>+49A/G*A allele with pSS in the first cohort of patients. When data were pooled (cohorts 1 and 2), no significant association was found with the <italic>CTLA-4 </italic>+49A/G polymorphism in our Caucasian population of patients with pSS. This was not the consequence of different origin or different clinico-biological characteristics of the patients from the two cohorts and could only be the result of a sampling bias. Indeed, the findings observed in our first cohort of patients, as those from Downie-Doyle and colleagues [<xref ref-type="bibr" rid="B3">3</xref>], were unexpected because there are only rare examples of association of the <italic>CTLA-4</italic>A/G*A allele with autoimmune diseases [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Consequently, we might have made premature conclusions if a replication study had not been performed.</p></sec><sec><title>Conclusion</title><p>Our study illustrates the necessity to include a large number of patients in genetic case-control studies. In fact, sampling bias may partly account for some contradictory results previously reported for <italic>CTLA-4 </italic>association studies in autoimmune diseases.</p></sec><sec><title>Abbreviations</title><p>CI = confidence interval; CTLA-4 = cytotoxic T lymphocyte-associated antigen-4; OR = odds ratio; pSS = primary Sj&#x000f6;gren syndrome; SNP = single nucleotide polymorphism.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JEG contributed to the study design, performed the statistical analysis and drafted the manuscript. PL and DC supervised genotyping and contributed to DNA samples collection. MA and CC performed genotyping. NC performed PHASE analyses. EH, XP, and JS contributed to DNA samples collection. XM and CMR supervised the study design and gave valuable advice to JEG and PL. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported by R&#x000e9;seau de recherche clinique INSERM.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kristiansen</surname><given-names>OP</given-names></name><name><surname>Larsen</surname><given-names>ZM</given-names></name><name><surname>Pociot</surname><given-names>F</given-names></name></person-group><article-title>CTLA-4 in autoimmune diseases &#x02013; a general susceptibility gene to autoimmunity?</article-title><source>Genes Immun</source><year>2000</year><volume>1</volume><fpage>170</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">11196709</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6363655</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>H</given-names></name><name><surname>Howson</surname><given-names>JM</given-names></name><name><surname>Esposito</surname><given-names>L</given-names></name><name><surname>Heward</surname><given-names>J</given-names></name><name><surname>Snook</surname><given-names>H</given-names></name><name><surname>Chamberlain</surname><given-names>G</given-names></name><name><surname>Rainbow</surname><given-names>DB</given-names></name><name><surname>Hunter</surname><given-names>KM</given-names></name><name><surname>Smith</surname><given-names>AN</given-names></name><name><surname>Di Genova</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Association of the T-cell regulatory gene <italic>CTLA4 </italic>with susceptibility to autoimmune disease</article-title><source>Nature</source><year>2003</year><volume>423</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">12724780</pub-id><pub-id pub-id-type="doi">10.1038/nature01621</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Downie-Doyle</surname><given-names>S</given-names></name><name><surname>Bayat</surname><given-names>N</given-names></name><name><surname>Rischmueller</surname><given-names>M</given-names></name><name><surname>Lester</surname><given-names>S</given-names></name></person-group><article-title>Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome</article-title><source>Arthritis Rheum</source><year>2006</year><volume>54</volume><fpage>2434</fpage><lpage>2440</lpage><pub-id pub-id-type="pmid">16869018</pub-id><pub-id pub-id-type="doi">10.1002/art.22004</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vitali</surname><given-names>C</given-names></name><name><surname>Bombardieri</surname><given-names>S</given-names></name><name><surname>Jonsson</surname><given-names>R</given-names></name><name><surname>Moutsopoulos</surname><given-names>HM</given-names></name><name><surname>Alexander</surname><given-names>EL</given-names></name><name><surname>Carsons</surname><given-names>SE</given-names></name><name><surname>Daniels</surname><given-names>TE</given-names></name><name><surname>Fox</surname><given-names>PC</given-names></name><name><surname>Fox</surname><given-names>RI</given-names></name><name><surname>Kassan</surname><given-names>SS</given-names></name><etal></etal></person-group><article-title>Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group</article-title><source>Ann Rheum Dis</source><year>2002</year><volume>61</volume><fpage>554</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">12006334</pub-id><pub-id pub-id-type="doi">10.1136/ard.61.6.554</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Djilali-Saiah</surname><given-names>I</given-names></name><name><surname>Schmitz</surname><given-names>J</given-names></name><name><surname>Harfouch-Hammoud</surname><given-names>E</given-names></name><name><surname>Mougenot</surname><given-names>JF</given-names></name><name><surname>Bach</surname><given-names>JF</given-names></name><name><surname>Caillat-Zucman</surname><given-names>S</given-names></name></person-group><article-title>CTLA-4 gene polymorphism is associated with predisposition to coeliac disease</article-title><source>Gut</source><year>1998</year><volume>43</volume><fpage>187</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">10189842</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suppiah</surname><given-names>V</given-names></name><name><surname>O'Doherty</surname><given-names>C</given-names></name><name><surname>Heggarty</surname><given-names>S</given-names></name><name><surname>Patterson</surname><given-names>CC</given-names></name><name><surname>Rooney</surname><given-names>M</given-names></name><name><surname>Vandenbroeck</surname><given-names>K</given-names></name></person-group><article-title>The CTLA4+49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland</article-title><source>Exp Mol Pathol</source><year>2006</year><volume>80</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">16248997</pub-id><pub-id pub-id-type="doi">10.1016/j.yexmp.2005.09.004</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hadj Kacem</surname><given-names>H</given-names></name><name><surname>Bellassoued</surname><given-names>M</given-names></name><name><surname>Bougacha-Elleuch</surname><given-names>N</given-names></name><name><surname>Abid</surname><given-names>M</given-names></name><name><surname>Ayadi</surname><given-names>H</given-names></name></person-group><article-title>CTLA-4 gene polymorphisms in Tunisian patients with Graves' disease</article-title><source>Clin Immunol</source><year>2001</year><volume>101</volume><fpage>361</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">11726229</pub-id><pub-id pub-id-type="doi">10.1006/clim.2001.5121</pub-id></citation></ref></ref-list></back></article> 